
The U.S. Food and Drug Administration approved on Monday PTC Therapeutics, Inc.’s (NASDAQ:PTCT) SEPHIENCE (sepiapterin) for children and adult patients with phenylketonuria (PKU).
PTCT stock is on the move, climbing higher. Check the latest price here.